Publication Beamlines Strategic Pillar
(2024). Exit Window for Electron Beam in Isotope Production. Patent Number: IL268283B2.
(2019). Prolactin receptor binding proteins and uses thereof. Patent Number: IL239502B.
(2021). Methods for improving response to anti-lif antibody treatment in individuals with cancer. Patent Number: IL279484A.
(2023). CORE/CASING ENGINEERING WITH GAPS (CSVE) OF CATALYST FOR ELECTROCHEMICAL CO2 REDUCTION. Patent Number: PT3791010T.
(2020). Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer. Patent Number: IL277918A.
(2021). Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer. Patent Number: IL279444A.
(2021). ANTIBODY. Patent Number: PT3311170T.
(2024). Antibodies that bind to a complex containing TNF from the TNF superfamily and a small molecule that is its modulator. Patent Number: IL256099B2.
(2022). Surgical method for treatment of auditory disease or condition. Patent Number: GB202213060D0.
(2025). ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING BCMA AND CD3 AND THEIR USES. Patent Number: FR23C1012I2.
(2023). Antibodies to tigit. Patent Number: IL298111A.
(2023). ANTI-BCMA ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND BCMA AND CD3, AND USES THEREOF. Patent Number: CY2023007I2.
(2023). teclistamab. Patent Number: NL301219I2.
(2023). ANTI-BCMA ANTIBODIES, BCMA AND CD3-BINDING BISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF. Patent Number: FR23C1011I1.
(2022). Nanoparticle platform for antibody and vaccine delivery. Patent Number: PT3661968T.